Wells Fargo & Company Increases Merck & Co., Inc. (NYSE:MRK) Price Target to $150.00

Merck & Co., Inc. (NYSE:MRK) had its price objective raised by investment analysts at Wells Fargo & Company from $135.00 to $150.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 29.75% from the stock’s current price.

MRK has been the subject of several other reports. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research note on Friday, February 13th. The Goldman Sachs Group upped their target price on Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Cantor Fitzgerald increased their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Citigroup raised their price target on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, Royal Bank Of Canada assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, February 25th. They set an “outperform” rating and a $142.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $126.81.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $115.61 on Thursday. The company’s fifty day moving average is $115.26 and its two-hundred day moving average is $99.58. The company has a market cap of $285.84 billion, a P/E ratio of 15.88, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same quarter last year, the firm posted $1.72 earnings per share. Merck & Co., Inc.’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Robert M. Davis sold 47,434 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the sale, the chief executive officer directly owned 443,602 shares of the company’s stock, valued at $52,362,780.08. This trade represents a 9.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 320,176 shares of company stock worth $38,281,735. Insiders own 0.13% of the company’s stock.

Institutional Trading of Merck & Co., Inc.

A number of institutional investors have recently added to or reduced their stakes in MRK. Chesapeake Wealth Management grew its position in Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after acquiring an additional 87 shares in the last quarter. South Plains Financial Inc. increased its stake in Merck & Co., Inc. by 0.6% during the fourth quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after purchasing an additional 89 shares during the period. Syverson Strege & Co lifted its position in shares of Merck & Co., Inc. by 2.2% during the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 3.1% during the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock worth $331,000 after purchasing an additional 93 shares in the last quarter. Finally, Valued Wealth Advisors LLC boosted its stake in shares of Merck & Co., Inc. by 26.9% in the fourth quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock valued at $47,000 after purchasing an additional 94 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.